Novartis seeks U.S., European approval for breast cancer drug

07/12/2005 | Reuters

The Swiss drugmaker is seeking regulatory approval for its breast cancer drug Femara to be used immediately after surgery to help post-menopausal women fight tumors. The drug already is approved for patients who have completed a five-year post-surgery treatment with tamoxifen, but Novartis said Femara, an aromatase inhibitor, has demonstrated greater effectiveness in preventing a cancer recurrence.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Associate Manager, Regulatory Affairs
Mahwah, NJ
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC